Linda Hermiller, MD
Endocrinology, Diabetes & Metabolism · Covington, KYNPI 1932142734
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Lilly USA, LLC at 36.2% of the total. Reporting peaked in 2024 at $6,598 and has fallen 65.1% since, to $2,300 in 2025.
Across 230 payments — averaging $50.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$4K
- Boehringer Ingelheim$3K
- Dexcom, Inc.$1K
- Medtronic$730
- Amgen$722
- Novo Nordisk$262
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$6,01352%
- Travel & lodging$8177%
- Food & beverage$4,81241%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $4,221 |
| Boehringer Ingelheim | 11 | $2,906 |
| Dexcom, Inc. | 37 | $1,069 |
| Medtronic(2 entities) | 37 | $730 |
| Amgen(2 entities) | 26 | $722 |
| Novo Nordisk | 17 | $262 |
| Sequel Med Tech, LLC | 2 | $251 |
| Corcept Therapeutics | 8 | $248 |
| Abbott | 14 | $201 |
| Pfizer | 14 | $193 |
| Sanofi-aventis U.S. LLC | 7 | $109 |
| Antares Pharma, Inc. | 5 | $91 |
| AstraZeneca | 4 | $65 |
| Lifescan, Inc. | 4 | $62 |
| Eisai Inc. | 3 | $51 |
| Amarin Pharma, Inc. | 3 | $49 |
| Insulet Corporation | 3 | $45 |
| Radius Health, Inc. | 3 | $43 |
| Ascendis Pharma Endocrinology Inc | 2 | $39 |
| Madrigal Pharmaceuticals | 1 | $33 |
| Vivus LLC | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| Novartis | 1 | $27 |
| Johnson & Johnson | 2 | $24 |
| Mannkind Corporation | 1 | $20 |
| Averitas Pharma Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| IBSA Pharma Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$6,834
- TWIIST$251
- Korlym$125
- TEPEZZA$124
- DEXCOM G6 TRANSMITTER$115
- Minimed 670G System$101
How this compares
$11,653 in reported general payments places this provider in the 75th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 303 | $439,267 |
| JardianceEmpagliflozin | 239 | $304,007 |
| TrulicityDulaglutide | 123 | $209,551 |
| MounjaroTirzepatide | 120 | $154,575 |
| JanuviaSitagliptin Phosphate | 136 | $136,056 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $79,433 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $79,295 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $63,283 |
| TradjentaLinagliptin | 51 | $56,511 |
| Tresiba Flextouch U-100Insulin Degludec | 76 | $55,839 |
| FarxigaDapagliflozin Propanediol | 46 | $54,620 |
| Novolog FlexpenInsulin Aspart | 115 | $49,682 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 61 | $40,313 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 199 | $34,251 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $28,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $262 | $444,889331 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $4,221 | $370,545268 claims |
| Boehringer IngelheimJardiance, Tradjenta | $2,906 | $360,519290 claims |
| AstraZenecaFarxiga | $65 | $54,62046 claims |
| AbbVieSynthroid | $15 | $12,485200 claims |
| Sanofi-aventis U.S. LLCLantus | $109 | $4,73544 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Covington
- Yancey HolmesCovington$148K
- Wael EidCovington$31K
- Jaspreet ChahalCovington$11K
- Ailleen Heras HerzigCovington$5K
- Irina KorablevaCovington$4K
- Bradley EilermanFlorence$1.3M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.